138
Participants
Start Date
February 29, 2012
Primary Completion Date
January 31, 2013
Study Completion Date
October 31, 2013
Elsiglutide
24 mg administered s.c. once daily for 4 consecutive days from Day 1 chemotherapy
Placebo
24 mg administered s.c. once daily for 4 consecutive days from Day 1 chemotherapy
Department of Chemotherapy Specialized Hospital for Active Treatment of Oncological Diseases, Sofia
Department of Chemotherapy Specialized Hospital for Active Treatment of Oncological Diseases, Sofia
Department of Chemotherapy, Complex Oncology Center, Rousse
"Oncology Clinic, Multiprofile Hospital for Active Treatment Sveta Marina", Varna
Petz Aladar County Teaching Hospital, Center of Oncologic Radiology Hungary, Győr
Chemotherapy Department, Complex Oncology Center, Shumen
Regional Oncology Hospital, Yaroslavl
Regional Oncology Center, Arkhangelsk
City #9 Hospital, Saint Petersburg
City Clinical Oncology Center, Saint Petersburg
Kursk Regional Clinical Oncology Center, Kursk
Pyatigorsk Oncology Center, Pyatigorsk
Prof. Dr. Ion Chiricuta Institute of Oncology, Medical Oncology Department, Cluj-Napoca
Dr. Constantin Opris Clinical Country Emergency Hospital Baia Mare, Department of Oncology, Baia Mare
Regional Clinical Oncology Center - Chemotherapy Department, Ulyanovsk
Euroclinic Oncology Center SRL - Medical Oncology Department, Iași
Sf. Ioan cel Nou Emergency Clincal County Hospital, Suceava
Semmelweis University, Department of Diagnostic Radiology and Oncotherapy, Budapest
Kenezy Hospital, Department of Clinical Pharmacology, Infectology and Allergology, Debrecen
Szeged Medical University Department of Oncology and Oncotherapy, Szeged
Fundeni Clinical Institute - Medical Oncology Department, Bucharest
Lead Sponsor
Helsinn Healthcare SA
INDUSTRY